| Mr Powell Perng, | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-5000 | |
| Not Available |
| Full Name | Mr Powell Perng |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 7 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528459815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 12192581-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Dermatology Skin Cancer And Laser Surgery Center P.c. | 6709775133 | 14 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The first direct comparison of in vitro and in vivo screening techniques for identifying nanoparticles that may be used to transport therapeutic molecules into cells shows that testing in lab dishes isn't much help in predicting which nanoparticles will successfully enter the cells of living animals.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research.
Transcatheter aortic valve replacement is a revolutionary technology for the treatment of patients with severe calcific aortic stenosis.
› Verified 2 days ago
| Entity Name | Advanced Dermatology Skin Cancer & Laser Surgery Center P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134170012 PECOS PAC ID: 6709775133 Enrollment ID: O20040313000244 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The first direct comparison of in vitro and in vivo screening techniques for identifying nanoparticles that may be used to transport therapeutic molecules into cells shows that testing in lab dishes isn't much help in predicting which nanoparticles will successfully enter the cells of living animals.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research.
Transcatheter aortic valve replacement is a revolutionary technology for the treatment of patients with severe calcific aortic stenosis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Powell Perng, 733 Rutland Avenue, Baltimore, MD 21205-2109 Ph: (410) 955-3080 | Mr Powell Perng, 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-5000 |
News Archive
Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin's lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.
The first direct comparison of in vitro and in vivo screening techniques for identifying nanoparticles that may be used to transport therapeutic molecules into cells shows that testing in lab dishes isn't much help in predicting which nanoparticles will successfully enter the cells of living animals.
Nu Skin Enterprises, Inc. announced today the closing of a partial over-allotment option exercise by the underwriters of 569,000 shares of its Class A common stock at $27.00 per share, pursuant to an option granted to the underwriters in connection with its previously announced underwritten secondary public offering of 4.46 million shares of its Class A common stock at $27.00 per share.
Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research.
Transcatheter aortic valve replacement is a revolutionary technology for the treatment of patients with severe calcific aortic stenosis.
› Verified 2 days ago
Sarah Nakib, MD, MPH Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Baltimore, MD 21287 Phone: 410-955-8662 | |
Elizabeth Tanzi, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-6776 | |
Crystal Ugochi Aguh, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1550 Orleans St, Crb Ii Room 211, Baltimore, MD 21287 Phone: 410-955-2400 Fax: 410-955-8645 | |
Dr. Larry H Gaston, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2300 Garrison Blvd, Suite 260, Baltimore, MD 21216 Phone: 410-945-7544 Fax: 410-945-3605 | |
Dr. Manisha J. Loss, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St, Suite 8060b, Baltimore, MD 21287 Phone: 410-502-2082 | |
Dr. Marcia Sanford Driscoll, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 419 W Redwood St, Suite 160, Baltimore, MD 21201 Phone: 410-328-3167 Fax: 410-328-1323 | |
Dr. Myriam Lucia Vega Gonzalez, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 601 N Caroline St # 8072, Baltimore, MD 21287 Phone: 410-955-5933 Fax: 410-502-2309 |